Literature DB >> 22778457

Piperacillin/tazobactam induced thrombocytopaenia--a delayed response.

Jessica L Macwilliam1, Rahul Mistry, Michael S Floyd, Andrew D Baird.   

Abstract

A 48-year-old lady who presented with sepsis secondary to a pelvi-ureteric junction obstruction was treated with an extended course of piperacillin/tazobactam. Four days after completing the course she developed thrombocytopaenia. Intravenous immunoglobulin was required to bring her platelet count back to normal. In the absence of other causes the authors believe that a delayed reaction to piperacillin/tazobactam was the cause of her thrombocytopaenia.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22778457      PMCID: PMC3417021          DOI: 10.1136/bcr.03.2012.5981

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  10 in total

1.  Piperacillin/tazobactam-induced paresthesiae.

Authors:  Jonathan Lambourne; Joanne Kitchen; Claudine Hughes; Concepta Merry
Journal:  Ann Pharmacother       Date:  2006-04-18       Impact factor: 3.154

Review 2.  Drug-induced thrombocytopenia: a systematic review of published case reports.

Authors:  J N George; G E Raskob; S R Shah; M A Rizvi; S A Hamilton; S Osborne; T Vondracek
Journal:  Ann Intern Med       Date:  1998-12-01       Impact factor: 25.391

3.  Immune thrombocytopenia caused by piperacillin/tazobactam.

Authors:  A Pérez-Vázquez; J M Pastor; J A Riancho
Journal:  Clin Infect Dis       Date:  1998-09       Impact factor: 9.079

4.  Leukocytopenia, thrombocytopenia and fever related to piperacillin/tazobactam treatment--a retrospective analysis in 38 children with cystic fibrosis.

Authors:  P Reichardt; W Handrick; A Linke; R Schille; W Kiess
Journal:  Infection       Date:  1999 Nov-Dec       Impact factor: 3.553

5.  A method for estimating the probability of adverse drug reactions.

Authors:  C A Naranjo; U Busto; E M Sellers; P Sandor; I Ruiz; E A Roberts; E Janecek; C Domecq; D J Greenblatt
Journal:  Clin Pharmacol Ther       Date:  1981-08       Impact factor: 6.875

Review 6.  Systematic review of piperacillin-induced neutropenia.

Authors:  Marc H Scheetz; June M McKoy; Jorge P Parada; Benjamin Djulbegovic; Dennis W Raisch; Paul R Yarnold; Jessica Zagory; Steve Trifilio; Rita Jakiche; Frank Palella; Adam Kahn; Kevin Chandler; Charles L Bennett
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

Review 7.  Mechanisms of drug-induced delayed-type hypersensitivity reactions in the skin.

Authors:  Sanjoy Roychowdhury; Craig K Svensson
Journal:  AAPS J       Date:  2005-12-09       Impact factor: 4.009

8.  Piperacillin and vancomycin induced severe thrombocytopenia in a hospitalized patient.

Authors:  Amritpal Anand; Hiteshi K C Chauhan
Journal:  Platelets       Date:  2011-02-10       Impact factor: 3.862

Review 9.  Drug-induced immune thrombocytopenia: pathogenesis, diagnosis, and management.

Authors:  R H Aster; B R Curtis; J G McFarland; D W Bougie
Journal:  J Thromb Haemost       Date:  2009-04-02       Impact factor: 5.824

10.  Recurrent acute thrombocytopenia in the hospitalized patient: sepsis, DIC, HIT, or antibiotic-induced thrombocytopenia.

Authors:  Talla A Rousan; Ibrahim T Aldoss; Benjamin D Cowley; Brian R Curtis; Daniel W Bougie; Richard H Aster; James N George
Journal:  Am J Hematol       Date:  2010-01       Impact factor: 10.047

  10 in total
  3 in total

Review 1.  Is Piperacillin-Tazobactam an Appropriate Empirical Agent for Hospital-Acquired Sepsis and Community-Acquired Septic Shock of Unknown Origin in Australia?

Authors:  Alice Gage-Brown; Catherine George; Jenna Maleki; Kasha P Singh; Stephen Muhi
Journal:  Healthcare (Basel)       Date:  2022-05-05

2.  Tazobactam and piperacillin-induced thrombocytopenia: A case report.

Authors:  Hong Chen; Zhen Fan; Fei Guo; Yumin Yang; Jie Li; Jie Zhang; Yudan Wang; Jianwei LE; Zhiyu Wang; Jianhua Zhu
Journal:  Exp Ther Med       Date:  2016-02-09       Impact factor: 2.447

Review 3.  Pharmacokinetics-pharmacodynamics issues relevant for the clinical use of beta-lactam antibiotics in critically ill patients.

Authors:  Rui Pedro Veiga; José-Artur Paiva
Journal:  Crit Care       Date:  2018-09-24       Impact factor: 9.097

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.